rood blauwe elepsis logo Belegger.nl

Galapagos 200 euro per aandeel

957 Posts
Pagina: «« 1 ... 13 14 15 16 17 ... 48 »» | Laatste | Omlaag ↓
  1. [verwijderd] 2 april 2018 21:13
    Introductie Filgotinib door Gilead nabij !!!!,

    We have the following exciting opportunity in our Foster City, CA location:Associate Director Opinion Leader Programs (OLP), Rheumatoid Arthritis (RA) MarketingThis role is a foundational role and the beginning of a core build of the US marketing team for the launch of FILGOTINIB in Rheumatoid Arthritis. As one of the first members of the US commercial team, this individual will assume a key leadership role responsible for a multitude of OLP-related activities in preparing the US commercial organization and the external marketplace for this important launch into a novel therapeutic area for Gilead.

    jobs.adweek.com/job/associate-directo...
  2. Bruyne 2 april 2018 21:42
    Kost niets om iemand aan te nemen in geval van. Alleszins de markt reageert hier niet op. Wil hiermee niets afbreken, zit ook long...
  3. [verwijderd] 2 april 2018 22:12
    quote:

    inspirator schreef op 2 april 2018 21:13:

    Introductie Filgotinib door Gilead nabij !!!!,

    We have the following exciting opportunity in our Foster City, CA location:Associate Director Opinion Leader Programs (OLP), Rheumatoid Arthritis (RA) MarketingThis role is a foundational role and the beginning of a core build of the US marketing team for the launch of FILGOTINIB in Rheumatoid Arthritis. As one of the first members of the US commercial team, this individual will assume a key leadership role responsible for a multitude of OLP-related activities in preparing the US commercial organization and the external marketplace for this important launch into a novel therapeutic area for Gilead.

    jobs.adweek.com/job/associate-directo...

    Ook Gilead laat activteit zien rondom Filgotinib.
    Als je deze vacature leest van Gilead aangaande marktintroduktie van Filgotinib, dan wordt Filgotinib een megabuster.

  4. aston.martin 2 april 2018 22:33
    quote:

    inspirator schreef op 2 april 2018 16:48:

    [...]

    In ieder geval komt er nieuws van Galapagos

    Open deze link

    www.biopharmcatalyst.com/calendars/fd...

    Zoek naar glpg

    En zie daar 4 april aankondigingen,

    Verdorie, je hebt gelijk: 4 april,aankondigingen!!!

    Een klein detail echter: de aankondigingen waren 4 april 2017.

    Nu dacht ik dat we ondertussen al wel in 2018 zijn...
    Lange winterslaap gedaan zeker?

    En dat de studies eind Q2 pas afgelopen zijn heb je niet gelezen waarschijnlijk.

    Die 4 april is gewoon de dag dat Galapagos vorig jaar de start van de studies heeft aangekondigd.

    Man, man, man... en jij hebt het lef om Onno een CEO onwaardig te noemen.

    Beschamend gewoon

  5. [verwijderd] 2 april 2018 22:53
    Beschamend is dat Onno vd Stolpe grote verhalen ophangt en dat hij aandeelhouders op korte ternijn beloofd, dit in de publiciteit te brengen. En vervolgens blijft het stil.

    Q2 komt er in ieder geval nieuws.

  6. [verwijderd] 2 april 2018 22:54
    quote:

    inspirator schreef op 2 april 2018 21:13:

    Introductie Filgotinib door Gilead nabij !!!!,

    We have the following exciting opportunity in our Foster City, CA location:Associate Director Opinion Leader Programs (OLP), Rheumatoid Arthritis (RA) MarketingThis role is a foundational role and the beginning of a core build of the US marketing team for the launch of FILGOTINIB in Rheumatoid Arthritis. As one of the first members of the US commercial team, this individual will assume a key leadership role responsible for a multitude of OLP-related activities in preparing the US commercial organization and the external marketplace for this important launch into a novel therapeutic area for Gilead.

    jobs.adweek.com/job/associate-directo...

    Wauw
  7. nelis h 2 april 2018 23:14
    quote:

    moneymaker_BX schreef op 2 april 2018 23:11:

    Wat heeft dit van doen met Galapagos?
    Filgotinib en RA hebben inderdaad niets met galapagos van doen ...
  8. [verwijderd] 3 april 2018 07:18
    quote:

    inspirator schreef op 2 april 2018 21:13:

    Introductie Filgotinib door Gilead nabij !!!!,

    We have the following exciting opportunity in our Foster City, CA location:Associate Director Opinion Leader Programs (OLP), Rheumatoid Arthritis (RA) MarketingThis role is a foundational role and the beginning of a core build of the US marketing team for the launch of FILGOTINIB in Rheumatoid Arthritis. As one of the first members of the US commercial team, this individual will assume a key leadership role responsible for a multitude of OLP-related activities in preparing the US commercial organization and the external marketplace for this important launch into a novel therapeutic area for Gilead.

    jobs.adweek.com/job/associate-directo...

    launch of FILGOTINIB in Rheumatoid Arthritis
  9. [verwijderd] 3 april 2018 17:02
    quote:

    inspirator schreef op 2 april 2018 22:53:

    Beschamend is dat Onno vd Stolpe grote verhalen ophangt en dat hij aandeelhouders op korte ternijn beloofd, dit in de publiciteit te brengen. En vervolgens blijft het stil.

    Q2 komt er in ieder geval nieuws.

    Nou Onno heeft de prijs gewonnen:

    Meest waardeloze CEO van q1 2018

    Gelukkig komt er morgen nieuws

  10. [verwijderd] 4 april 2018 07:34
    Gilead gaat vaart zetten achter introduktie Filgotinib.

    Implement and evolve current filgotinib global market development strategic plan and communication platform.

    www.glassdoor.nl/job-listing/director...,41_KE42,57.htm?jl=2552748938&countryRedirect=true

    ps mooie functie voor Onno vd Stolpe: kan hij zich weer eens uitleven op zijn job.

    In ieder geval bevestiging dat Filgotinib een succesvol produkt is; nu nog de marktintroduktie.

    For Current Gilead Employees and Contractors:

    Please log onto your Internal Career Site to apply for this job.

    Job Description

    Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Asia, Europe and Australia.

    We have the following exciting opportunity in our Foster City, CA location:

    Specific Responsibilities

    Reporting to the Senior Director (Inflammations & Respiratory), Commercial Planning (CP), this role will oversee market preparation in RA/IBD and future indications for filgotinib (e.g., Ankylosing Spondilitis, Psoriatic Arthritis, Uveitis, etc). The candidate will be accountable for collaborative commercialization plan and strategy development in coordination with regional teams.

    Essential Duties and Job Functions
    Implement and evolve current filgotinib global market development strategic plan and communication platform.
    Partner with Sr Director and key stakeholders including regional teams, R&D, biomarkers team, medical affairs, and business development to develop a market development plan
    Develop and evolve tactical market development plan and communication plan in collaboration with clinical and medical affairs, including conference presence
    Collaborate closely with other members of cross functional team (market research, payer & market access, competitive intelligence, and Senior Director)
    Design and implement a process to ensure adoption of global market development deliverables by regional and country operations.
    Work closely with SD to develop and execute efficient global governance for inflammation
    Lead the strategic planning process in 2018 ensuring collaboration with cross functional teams.
    Lead by example, respecting Gilead core values of integrity, teamwork, accountability, excellence, diversity and inclusion.
    Knowledge, Experience and Skills
    The ideal candidate will be a proven business leader with a passion for commercializing breakthrough medicine, a global mindset, strong scientific acumen, strategic thinking.
    A successful candidate will have understanding and experience in pre-launch market development work in disease areas
    Demonstrated ability to develop successful partnership including the following functions – R&D, Medical affairs, Pricing & access, Health economics/Outcomes Research, Policy, government affairs, public affairs.
    Position requires proven “leading and influencing without authority” skills.
    Successful candidate needs to have a deep understanding of the evolving payer and market landscapes, health reforms, and can anticipate and prioritize what is needed in these rapidly evolving landscapes with extremely challenging healthcare economics.
    Prior experience in developing a market in early disease life cycle is preferred.
    Bachelor’s degree is required (advanced degree in life sciences or M.B.A. preferred)
    10+ years’ experience in the biopharmaceutical industry. Experiences to include global product strategic planning, in-country marketing, new product planning, portfolio management and lifecycle management
  11. [verwijderd] 4 april 2018 08:38
    quote:

    inspirator schreef op 4 april 2018 07:34:

    Gilead gaat vaart zetten achter introduktie Filgotinib.

    Implement and evolve current filgotinib global market development strategic plan and communication platform.

    www.glassdoor.nl/job-listing/director...,41_KE42,57.htm?jl=2552748938&countryRedirect=true

    ps mooie functie voor Onno vd Stolpe: kan hij zich weer eens uitleven op zijn job.

    In ieder geval bevestiging dat Filgotinib een succesvol produkt is; nu nog de marktintroduktie.

    For Current Gilead Employees and Contractors:

    Please log onto your Internal Career Site to apply for this job.

    Job Description

    Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Asia, Europe and Australia.

    We have the following exciting opportunity in our Foster City, CA location:

    Specific Responsibilities

    Reporting to the Senior Director (Inflammations & Respiratory), Commercial Planning (CP), this role will oversee market preparation in RA/IBD and future indications for filgotinib (e.g., Ankylosing Spondilitis, Psoriatic Arthritis, Uveitis, etc). The candidate will be accountable for collaborative commercialization plan and strategy development in coordination with regional teams.

    Essential Duties and Job Functions
    Implement and evolve current filgotinib global market development strategic plan and communication platform.
    Partner with Sr Director and key stakeholders including regional teams, R&D, biomarkers team, medical affairs, and business development to develop a market development plan
    Develop and evolve tactical market development plan and communication plan in collaboration with clinical and medical affairs, including conference presence
    Collaborate closely with other members of cross functional team (market research, payer & market access, competitive intelligence, and Senior Director)
    Design and implement a process to ensure adoption of global market development deliverables by regional and country operations.
    Work closely with SD to develop and execute efficient global governance for inflammation
    Lead the strategic planning process in 2018 ensuring collaboration with cross functional teams.
    Lead by example, respecting Gilead core values of integrity, teamwork, accountability, excellence, diversity and inclusion.
    Knowledge, Experience and Skills
    The ideal candidate will be a proven business leader with a passion for commercializing breakthrough medicine, a global mindset, strong scientific acumen, strategic thinking.
    A successful candidate will have understanding and experience in pre-launch market development work in disease areas
    Demonstrated ability to develop successful partnership including the following functions – R&D, Medical affairs, Pricing & access, Health economics/Outcomes Research, Policy, government affairs, public affairs.
    Position requires proven “leading and influencing without authority” skills.
    Successful candidate needs to have a deep understanding of the evolving payer and market landscapes, health reforms, and can anticipate and prioritize what is needed in these rapidly evolving landscapes with extremely challenging healthcare economics.
    Prior experience in developing a market in early disease life cycle is preferred.
    Bachelor’s degree is required (advanced degree in life sciences or M.B.A. preferred)
    10+ years’ experience in the biopharmaceutical industry. Experiences to include global product strategic planning, in-country marketing, new product planning, portfolio management and lifecycle management
    Prima
  12. [verwijderd] 4 april 2018 11:27
    quote:

    inspirator schreef op 4 april 2018 07:34:

    Gilead gaat vaart zetten achter introduktie Filgotinib.

    Implement and evolve current filgotinib global market development strategic plan and communication platform.

    www.glassdoor.nl/job-listing/director...,41_KE42,57.htm?jl=2552748938&countryRedirect=true

    ps mooie functie voor Onno vd Stolpe: kan hij zich weer eens uitleven op zijn job.

    In ieder geval bevestiging dat Filgotinib een succesvol produkt is; nu nog de marktintroduktie.

    For Current Gilead Employees and Contractors:

    Please log onto your Internal Career Site to apply for this job.

    Job Description

    Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Asia, Europe and Australia.

    We have the following exciting opportunity in our Foster City, CA location:

    Specific Responsibilities

    Reporting to the Senior Director (Inflammations & Respiratory), Commercial Planning (CP), this role will oversee market preparation in RA/IBD and future indications for filgotinib (e.g., Ankylosing Spondilitis, Psoriatic Arthritis, Uveitis, etc). The candidate will be accountable for collaborative commercialization plan and strategy development in coordination with regional teams.

    Essential Duties and Job Functions
    Implement and evolve current filgotinib global market development strategic plan and communication platform.
    Partner with Sr Director and key stakeholders including regional teams, R&D, biomarkers team, medical affairs, and business development to develop a market development plan
    Develop and evolve tactical market development plan and communication plan in collaboration with clinical and medical affairs, including conference presence
    Collaborate closely with other members of cross functional team (market research, payer & market access, competitive intelligence, and Senior Director)
    Design and implement a process to ensure adoption of global market development deliverables by regional and country operations.
    Work closely with SD to develop and execute efficient global governance for inflammation
    Lead the strategic planning process in 2018 ensuring collaboration with cross functional teams.
    Lead by example, respecting Gilead core values of integrity, teamwork, accountability, excellence, diversity and inclusion.
    Knowledge, Experience and Skills
    The ideal candidate will be a proven business leader with a passion for commercializing breakthrough medicine, a global mindset, strong scientific acumen, strategic thinking.
    A successful candidate will have understanding and experience in pre-launch market development work in disease areas
    Demonstrated ability to develop successful partnership including the following functions – R&D, Medical affairs, Pricing & access, Health economics/Outcomes Research, Policy, government affairs, public affairs.
    Position requires proven “leading and influencing without authority” skills.
    Successful candidate needs to have a deep understanding of the evolving payer and market landscapes, health reforms, and can anticipate and prioritize what is needed in these rapidly evolving landscapes with extremely challenging healthcare economics.
    Prior experience in developing a market in early disease life cycle is preferred.
    Bachelor’s degree is required (advanced degree in life sciences or M.B.A. preferred)
    10+ years’ experience in the biopharmaceutical industry. Experiences to include global product strategic planning, in-country marketing, new product planning, portfolio management and lifecycle management
    Nou Onno,
    We komen vanaf vandaag iedere dagbij je eten.
    Kun tenminste nog iets klaarmaken voor je aandeelhouders.

    Tot vanavond.
    Lust trouwens alles en een goede wijn zouden we op prijs stellen.
  13. [verwijderd] 4 april 2018 14:51
    Media

    Nico PR Bakker
    ?

    @TheDailyTurbo
    3 min3 minuten geleden
    Meer Nico PR Bakker heeft geretweet Marjan Huisman
    #GALAPAGOS vervolgt zijn daily downtrend en valt onder de weekly SMA richting de onderkant van het stijgingskanaal rond 75,00...met deze voortgang wordt de TT Long Setup ingetrokken.....Nico PR Bakker heeft toegevoegd,
957 Posts
Pagina: «« 1 ... 13 14 15 16 17 ... 48 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.102
AB InBev 2 5.530
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.962
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.808
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.783
Aedifica 3 925
Aegon 3.258 323.009
AFC Ajax 538 7.088
Affimed NV 2 6.303
ageas 5.844 109.897
Agfa-Gevaert 14 2.062
Ahold 3.538 74.345
Air France - KLM 1.025 35.250
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.048
Alfen 16 25.110
Allfunds Group 4 1.514
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 409
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.644
AMG 971 134.105
AMS 3 73
Amsterdam Commodities 305 6.740
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.032
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.895
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.346
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.564
ASML 1.766 109.580
ASR Nederland 21 4.506
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.739
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.439